Results 211 to 220 of about 11,371 (259)

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs). [PDF]

Pituitary
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Schilbach K, Lely AJV, Wass JAH, Melmed S, Casanueva FF.   +18 more
europepmc   +1 more source

Efficacy of Local N-Acetylcysteine Administration in Mitigating OHSS Parameters: A Comparative Analysis With Dopaminergic Agonist in the OHSS Model. [PDF]

Int J Endocrinol
Letras-Luna DE, Rosas-Murrieta NH, Pazos-Salazar NG, Flores-Hernández J, Castelán F, Venegas B, Díaz A, Treviño S, Juárez-Serrano D, García-Suastegui WA, Handal-Silva A, Morán-Perales JL.   +11 more
europepmc   +1 more source

Predictors of biochemical and structural response to medical therapy in patients with active acromegaly following surgery: a real-world perspective. [PDF]

BMC Endocr Disord
Rafieemanesh M, Kachuee MA, Mehrjardi AZ, Khajavi A, Ghorbani M, Mohajeri-Tehrani MR, Hashemi-Madani N, Khamseh ME.   +7 more
europepmc   +1 more source

Letter to the Editor Regarding "The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series". [PDF]

J Neurol Surg Rep
Acitores Cancela A, Rodríguez Berrocal V, Pian-Arias H, Díez JJ, Iglesias P.   +4 more
europepmc   +1 more source

Biological mechanisms of dopamine D₂-like receptor agonist therapy in diabetes. [PDF]

Front Endocrinol (Lausanne)
Freyberg Z, Codario RA.
europepmc   +1 more source

Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors. [PDF]

Acta Neuropathol Commun
Martinez-Mendoza F, Andonegui-Elguera S, Sosa-Eroza E, Gomez-Apo E, Escobar-España A, Gonzalez-Torres C, Gaytan-Cervantes J, Palma-Guzman A, Torres-Flores H, Moscona-Nissan A, Hinojosa-Alvarez S, Hernandez-Perez J, Chavez-Santoscoy RA, Guinto G, Guinto-Nishimura GY, Lopez-Felix BE, Zepeda-Fernandez EU, Estrada-Estrada EM, Correa-Correa V, Gonzalez-Zavala PA, Asenscio-Montiel MA, Garcia-Vargas MA, Cantu-Chavez E, Arreola-Rosales RL, Taniguchi-Ponciano K, Marrero-Rodriguez D, Mercado M.   +26 more
europepmc   +1 more source

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. [PDF]

Pituitary
Hamblin R, White M, Fountas A, Karavitaki N.   +3 more
europepmc   +1 more source

Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study. [PDF]

Biomolecules
Krysiak R, Kowalcze K, Szkróbka W, Okopień B.   +3 more
europepmc   +1 more source

Microprolactinoma Growth During Pregnancy With Pituitary Tumor Apoplexy: Case Report and Review of the Literature. [PDF]

Case Rep Endocrinol
Introini L, Silva J, Risso M, Mendoza B, Pineyro MM.   +4 more
europepmc   +1 more source

Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance. [PDF]

J Neurooncol
Gu W, Zhang W, Wu Z, Cai Y.
europepmc   +1 more source